Skip to main content Skip to main navigation menu Skip to site footer
  • \
    Start Submission Become a Reviewer

    Guidelines for the Multidisciplinary Diagnosis and Treatment of Neurofibromatosis Type 1 (2023 Version) Multidisciplinary Diagnosis and Treatment Collaboration Group for Neurofibromatosis Type 1 of China Alliance for Rare Diseases

    • Yicheng Zhu


    Abstract

    Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary neoplastic disease caused by mutations in the NF1 gene. Features of the disorder typically appear in early childhood. The clinical phenotypes of the patients are diverse but neurofibroma is the main feature. Patients with NF1 also suffer from multi-system involvement and have high risk of malignant tumor. NF1 poses significant challenges for diagnosis, treatment, follow-up and patients management. Therefore, it is imperative to develop a multidisciplinary collaborative diagnosis and treatment protocol. Under the leadership of the China Alliance for Rare Diseases, a multidisciplinary diagnosis and treatment collaborative team for NF1 has been formed and  has developed the guideline. This guideline intends to lift the diagnosis and treatment level for NF1 and to provide a standardized treatment protocol for NF1 patients in China.

    Keywords: Neurofibromatosis type 1 Multidiscipline Guideline
    Section

    References

    1. Abdolrahimzadeh, S., Felli, L., Plateroti, R., Plateroti, A. M., Giustini, S., Calvieri, S., & Recupero, S. M. (2015). Morphologic and vasculature features of the choroid and associated choroid-retinal thickness alterations in neurofibromatosis type 1. Br J Ophthalmol, 99(6), 789-793. https://doi.org/10.1136/bjophthalmol-2014-306062
    2. Abouchadi, A., Nassih, M., Rzin, A., Elgbouri, H., & Jidal, B. (2005). [Orbito-temporal plexiform neurofibroma: 6 cases]. Rev Stomatol Chir Maxillofac, 106(5), 272-275. https://doi.org/10.1016/s0035-1768(05)86040-1 (Le neurofibrome plexiforme orbito-temporal: à propos de 6 cas.)
    3. Al-Sharefi, A., Javaid, U., Perros, P., Ealing, J., Truran, P., Nag, S., Kamaruddin, S., Abouglila, K., Cains, F., Lewis, L., & James, R. A. (2019). Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1. Eur Endocrinol, 15(2), 95-100. https://doi.org/10.17925/ee.2019.15.2.95
    4. Alshahrani, A., Abuoliat, Z., Alshahrani, A. S., & Al Balwi, M. A. (2022). Prevalence of Associated Endocrine Diseases in Patients with Neurofibromatosis Type 1. Avicenna J Med, 12(1), 16-20. https://doi.org/10.1055/s-0041-1742197
    5. Alwan, S., Tredwell, S. J., & Friedman, J. M. (2005). Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet, 67(5), 378-390. https://doi.org/10.1111/j.1399-0004.2005.00410.x
    6. Arrington, D. K., Danehy, A. R., Peleggi, A., Proctor, M. R., Irons, M. B., & Ullrich, N. J. (2013). Calvarial defects and skeletal dysplasia in patients with neurofibromatosis Type 1. J Neurosurg Pediatr, 11(4), 410-416. https://doi.org/10.3171/2013.1.Peds12409
    7. Artico, M., Cervoni, L., Wierzbicki, V., D'Andrea, V., & Nucci, F. (1997). Benign neural sheath tumours of major nerves: characteristics in 119 surgical cases. Acta Neurochir (Wien), 139(12), 1108-1116. https://doi.org/10.1007/bf01410969
    8. Asthagiri, A. R., Parry, D. M., Butman, J. A., Kim, H. J., Tsilou, E. T., Zhuang, Z., & Lonser, R. R. (2009). Neurofibromatosis type 2. Lancet, 373(9679), 1974-1986. https://doi.org/10.1016/s0140-6736(09)60259-2
    9. Barnett, C., Alon, T., Abraham, A., Kim, R. H., McCuaig, J. M., Kongkham, P., Maurice, C., Suppiah, S., Zadeh, G., & Bril, V. (2019). Evidence of small-fiber neuropathy in neurofibromatosis type 1. Muscle Nerve, 60(6), 673-678. https://doi.org/10.1002/mus.26687
    10. Barreto-Duarte, B., Andrade-Gomes, F. H., Arriaga, M. B., Araújo-Pereira, M., Cubillos-Angulo, J. M., & Andrade, B. B. (2021). Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review. PLoS One, 16(1), e0241096. https://doi.org/10.1371/journal.pone.0241096
    11. Beert, E., Brems, H., Daniëls, B., De Wever, I., Van Calenbergh, F., Schoenaers, J., Debiec-Rychter, M., Gevaert, O., De Raedt, T., Van Den Bruel, A., de Ravel, T., Cichowski, K., Kluwe, L., Mautner, V., Sciot, R., & Legius, E. (2011). Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer, 50(12), 1021-1032. https://doi.org/10.1002/gcc.20921
    12. Bellampalli, S. S., & Khanna, R. (2019). Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment. Pain, 160(5), 1007-1018. https://doi.org/10.1097/j.pain.0000000000001486
    13. Ben-Shachar, S., Constantini, S., Hallevi, H., Sach, E. K., Upadhyaya, M., Evans, G. D., & Huson, S. M. (2013). Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation. Eur J Hum Genet, 21(5), 535-539. https://doi.org/10.1038/ejhg.2012.221
    14. Bernardo, P., Cinalli, G., & Santoro, C. (2020). Epilepsy in NF1: a systematic review of the literature. Childs Nerv Syst, 36(10), 2333-2350. https://doi.org/10.1007/s00381-020-04710-7
    15. Bernthal, N. M., Putnam, A., Jones, K. B., Viskochil, D., & Randall, R. L. (2014). The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol, 110(7), 813-816. https://doi.org/10.1002/jso.23736
    16. Bizzarri, C., & Bottaro, G. (2015). Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr, 83(4), 232-241. https://doi.org/10.1159/000369802
    17. Boyce, A. M., & Collins, M. T. (2020). Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation. Endocr Rev, 41(2), 345-370. https://doi.org/10.1210/endrev/bnz011
    18. Champiat, S., Tselikas, L., Farhane, S., Raoult, T., Texier, M., Lanoy, E., Massard, C., Robert, C., Ammari, S., De Baère, T., & Marabelle, A. (2021). Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clin Cancer Res, 27(3), 665-679. https://doi.org/10.1158/1078-0432.Ccr-20-0473
    19. Chamseddin, B. H., & Le, L. Q. (2020). Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv, 2(Suppl 1), i107-i116. https://doi.org/10.1093/noajnl/vdz034
    20. Charles, S. J., Moore, A. T., Yates, J. R., & Ferguson-Smith, M. A. (1989). Lisch nodules in neurofibromatosis type 2. Case report. Arch Ophthalmol, 107(11), 1571-1572. https://doi.org/10.1001/archopht.1989.01070020649012
    21. Cheng, H., Shan, M., Feng, C., & Wang, X. (2014). Spinal cord ependymoma associated with neurofibromatosis 1 : case report and review of the literature. J Korean Neurosurg Soc, 55(1), 43-47. https://doi.org/10.3340/jkns.2014.55.1.43
    22. Clementi, M., Milani, S., Mammi, I., Boni, S., Monciotti, C., & Tenconi, R. (1999). Neurofibromatosis type 1 growth charts. Am J Med Genet, 87(4), 317-323. https://doi.org/10.1002/(sici)1096-8628(19991203)87:4<317::aid-ajmg7>3.0.co;2-x
    23. Cnossen, M. H., Stam, E. N., Cooiman, L. C., Simonsz, H. J., Stroink, H., Oranje, A. P., Halley, D. J., de Goede-Bolder, A., Niermeijer, M. F., & de Muinck Keizer-Schrama, S. M. (1997). Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics, 100(4), 667-670. https://doi.org/10.1542/peds.100.4.667
    24. Cook, G. J. R., Lovat, E., Siddique, M., Goh, V., Ferner, R., & Warbey, V. S. (2017). Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of (18)F-FDG PET. Eur J Nucl Med Mol Imaging, 44(11), 1845-1852. https://doi.org/10.1007/s00259-017-3733-1
    25. Créange, A., Zeller, J., Rostaing-Rigattieri, S., Brugières, P., Degos, J. D., Revuz, J., & Wolkenstein, P. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122 ( Pt 3), 473-481. https://doi.org/10.1093/brain/122.3.473
    26. Cui, X. W., Ren, J. Y., Gu, Y. H., Li, Q. F., & Wang, Z. C. (2020). NF1, Neurofibromin and Gene Therapy: Prospects of Next-Generation Therapy. Curr Gene Ther, 20(2), 100-108. https://doi.org/10.2174/1566523220666200806111451
    27. Danesh-Meyer, H. V., Carroll, S. C., Foroozan, R., Savino, P. J., Fan, J., Jiang, Y., & Vander Hoorn, S. (2006). Relationship between retinal nerve fiber layer and visual field sensitivity as measured by optical coherence tomography in chiasmal compression. Invest Ophthalmol Vis Sci, 47(11), 4827-4835. https://doi.org/10.1167/iovs.06-0327
    28. de Blank, P. M. K., Fisher, M. J., Liu, G. T., Gutmann, D. H., Listernick, R., Ferner, R. E., & Avery, R. A. (2017). Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol, 37 Suppl 1(Suppl 1), S23-s32. https://doi.org/10.1097/wno.0000000000000550
    29. de Leeuw, C. N., & Prayson, R. A. (2019). Primary intracranial rhabdomyosarcoma in an NF1 patient. Clin Neuropathol, 38(2), 84-86. https://doi.org/10.5414/np301133
    30. Donner, T. R., Voorhies, R. M., & Kline, D. G. (1994). Neural sheath tumors of major nerves. J Neurosurg, 81(3), 362-373. https://doi.org/10.3171/jns.1994.81.3.0362
    31. Dunning-Davies, B. M., & Parker, A. P. (2016). Annual review of children with neurofibromatosis type 1. Arch Dis Child Educ Pract Ed, 101(2), 102-111. https://doi.org/10.1136/archdischild-2014-308084
    32. Edward, D. P., Morales, J., Bouhenni, R. A., Patil, J., Edward, P. R., Cummings, T. J., Chaudhry, I. A., & Alkatan, H. (2012). Congenital ectropion uvea and mechanisms of glaucoma in neurofibromatosis type 1: new insights. Ophthalmology, 119(7), 1485-1494. https://doi.org/10.1016/j.ophtha.2012.01.027
    33. Elefteriou, F., Kolanczyk, M., Schindeler, A., Viskochil, D. H., Hock, J. M., Schorry, E. K., Crawford, A. H., Friedman, J. M., Little, D., Peltonen, J., Carey, J. C., Feldman, D., Yu, X., Armstrong, L., Birch, P., Kendler, D. L., Mundlos, S., Yang, F. C., Agiostratidou, G., Hunter-Schaedle, K., & Stevenson, D. A. (2009). Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A, 149a(10), 2327-2338. https://doi.org/10.1002/ajmg.a.33045
    34. Evans, D. G. R., Salvador, H., Chang, V. Y., Erez, A., Voss, S. D., Schneider, K. W., Scott, H. S., Plon, S. E., & Tabori, U. (2017). Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clin Cancer Res, 23(12), e46-e53. https://doi.org/10.1158/1078-0432.Ccr-17-0589
    35. Ferner, R. E., & Gutmann, D. H. (2013). Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol, 115, 939-955. https://doi.org/10.1016/b978-0-444-52902-2.00053-9
    36. Ferrari, F., Masurel, A., Olivier-Faivre, L., & Vabres, P. (2014). Juvenile xanthogranuloma and nevus anemicus in the diagnosis of neurofibromatosis type 1. JAMA Dermatol, 150(1), 42-46. https://doi.org/10.1001/jamadermatol.2013.6434
    37. Fisher, M. J., Shih, C. S., Rhodes, S. D., Armstrong, A. E., Wolters, P. L., Dombi, E., Zhang, C., Angus, S. P., Johnson, G. L., Packer, R. J., Allen, J. C., Ullrich, N. J., Goldman, S., Gutmann, D. H., Plotkin, S. R., Rosser, T., Robertson, K. A., Widemann, B. C., Smith, A. E., Bessler, W. K., He, Y., Park, S. J., Mund, J. A., Jiang, L., Bijangi-Vishehsaraei, K., Robinson, C. T., Cutter, G. R., Korf, B. R., Blakeley, J. O., & Clapp, D. W. (2021). Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med, 27(1), 165-173. https://doi.org/10.1038/s41591-020-01193-6
    38. Fossali, E., Signorini, E., Intermite, R. C., Casalini, E., Lovaria, A., Maninetti, M. M., & Rossi, L. N. (2000). Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol, 14(8-9), 806-810. https://doi.org/10.1007/s004679900260
    39. Friedman, J. M., Arbiser, J., Epstein, J. A., Gutmann, D. H., Huot, S. J., Lin, A. E., McManus, B., & Korf, B. R. (2002). Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med, 4(3), 105-111. https://doi.org/10.1097/00125817-200205000-00002
    40. Friedman, J. M., & Birch, P. H. (1997). Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet, 70(2), 138-143. https://doi.org/10.1002/(sici)1096-8628(19970516)70:2<138::aid-ajmg7>3.0.co;2-u
    41. Friedrich, R. E., Korf, B., Fünsterer, C., & Mautner, V. F. (2003). Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images. Anticancer Res, 23(2a), 949-952.
    42. Friedrich, R. E., Schmelzle, R., Hartmann, M., & Mautner, V. F. (2005). Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports. J Craniomaxillofac Surg, 33(1), 55-60. https://doi.org/10.1016/j.jcms.2004.08.004
    43. Gallon, R., Phelps, R., Hayes, C., Brugieres, L., Guerrini-Rousseau, L., Colas, C., Muleris, M., Ryan, N. A. J., Evans, D. G., Grice, H., Jessop, E., Kunzemann-Martinez, A., Marshall, L., Schamschula, E., Oberhuber, K., Azizi, A. A., Baris Feldman, H., Beilken, A., Brauer, N., Brozou, T., Dahan, K., Demirsoy, U., Florkin, B., Foulkes, W., Januszkiewicz-Lewandowska, D., Jones, K. J., Kratz, C. P., Lobitz, S., Meade, J., Nathrath, M., Pander, H. J., Perne, C., Ragab, I., Ripperger, T., Rosenbaum, T., Rueda, D., Sarosiek, T., Sehested, A., Spier, I., Suerink, M., Zimmermann, S. Y., Zschocke, J., Borthwick, G. M., Wimmer, K., Burn, J., Jackson, M. S., & Santibanez-Koref, M. (2023). Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency. Gastroenterology, 164(4), 579-592.e578. https://doi.org/10.1053/j.gastro.2022.12.017
    44. Gaonker, C. H., Mukherjee, A. K., & Pokle, M. (1992). Involvement of the eye and orbit in neurofibromatosis type 1. Indian J Ophthalmol, 40(1), 2-4.
    45. Garozzo, D. (2019). Peripheral nerve tumors in neurofibromatosis 1: An overview on management and indications for surgical treatment in our experience. Neurol India, 67(Supplement), S38-s44. https://doi.org/10.4103/0028-3886.250697
    46. Giussani, C., Isimbaldi, G., Massimino, M., Trezza, A., Cianci, P., Canonico, F., & Sganzerla, E. P. (2013). Ganglioglioma of the spinal cord in neurofibromatosis type 1. Pediatr Neurosurg, 49(1), 50-54. https://doi.org/10.1159/000355249
    47. Glad, D. M., Casnar, C. L., Yund, B. D., Lee, K., & Klein-Tasman, B. P. (2021). Parent-Reported Social Skills in Children with Neurofibromatosis Type 1: Longitudinal Patterns and Relations with Attention and Cognitive Functioning. J Dev Behav Pediatr, 42(8), 656-665. https://doi.org/10.1097/dbp.0000000000000939
    48. Gloster, H. M., Jr., & Roenigk, R. K. (1995). Carbon dioxide laser for the treatment of cutaneous lesions. Clin Dermatol, 13(1), 25-33. https://doi.org/10.1016/0738-081x(94)00024-v
    49. Gui, B., Yu, C., Li, X., Zhao, S., Zhao, H., Yan, Z., Cheng, X., Lin, J., Zheng, H., Shao, J., Zhao, Z., Zhao, L., Niu, Y., Zhao, Z., Wang, H., Xie, B., Wei, X., Gui, C., Li, C., Chen, S., Wang, Y., Song, Y., Gong, C., Zhang, T. J., Fan, X., Wu, Z., Chen, Y., & Wu, N. (2021). Heterozygous Recurrent Mutations Inducing Dysfunction of ROR2 Gene in Patients With Short Stature. Front Cell Dev Biol, 9, 661747. https://doi.org/10.3389/fcell.2021.661747
    50. Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017). Neurofibromatosis type 1. Nat Rev Dis Primers, 3, 17004. https://doi.org/10.1038/nrdp.2017.4
    51. Habiby, R., Silverman, B., Listernick, R., & Charrow, J. (1995). Precocious puberty in children with neurofibromatosis type 1. J Pediatr, 126(3), 364-367. https://doi.org/10.1016/s0022-3476(95)70449-3
    52. Hayashi, Y., Nakada, M., Mohri, M., Murakami, H., Kawahara, N., & Hamada, J. (2011). Ganglioglioma of the thoracolumbar spinal cord in a patient with neurofibromatosis type 1: a case report and literature review. Pediatr Neurosurg, 47(3), 210-213. https://doi.org/10.1159/000331569
    53. Higham, C. S., Dombi, E., Rogiers, A., Bhaumik, S., Pans, S., Connor, S. E. J., Miettinen, M., Sciot, R., Tirabosco, R., Brems, H., Baldwin, A., Legius, E., Widemann, B. C., & Ferner, R. E. (2018). The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol, 20(6), 818-825. https://doi.org/10.1093/neuonc/noy013
    54. Hwang, J., Yoon, H. M., Lee, B. H., Kim, P. H., & Kim, K. W. (2022). Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis. Neurology, 98(9), e938-e946. https://doi.org/10.1212/wnl.0000000000013296
    55. Jackson, I. T. (2001). Management of craniofacial neurofibromatosis. Facial Plast Surg Clin North Am, 9(1), 59-75, viii.
    56. Jacquemin, C., Bosley, T. M., Liu, D., Svedberg, H., & Buhaliqa, A. (2002). Reassessment of sphenoid dysplasia associated with neurofibromatosis type 1. AJNR Am J Neuroradiol, 23(4), 644-648.
    57. Jacquemin, C., Bosley, T. M., & Svedberg, H. (2003). Orbit deformities in craniofacial neurofibromatosis type 1. AJNR Am J Neuroradiol, 24(8), 1678-1682.
    58. Jeong, Y. H., Choi, E. J., & Nahm, F. S. (2013). Concurrence of malignant peripheral nerve sheath tumor at the site of complex regional pain syndrome type 1 - a case report. Korean J Pain, 26(2), 160-163. https://doi.org/10.3344/kjp.2013.26.2.160
    59. Kallionpää, R. A., Uusitalo, E., Leppävirta, J., Pöyhönen, M., Peltonen, S., & Peltonen, J. (2018). Prevalence of neurofibromatosis type 1 in the Finnish population. Genet Med, 20(9), 1082-1086. https://doi.org/10.1038/gim.2017.215
    60. Killock, D. (2020). Selumetinib benefits children with inoperable plexiform neurofibromas. Nat Rev Clin Oncol, 17(5), 273. https://doi.org/10.1038/s41571-020-0361-7
    61. Koczkowska, M., Callens, T., Chen, Y., Gomes, A., Hicks, A. D., Sharp, A., Johns, E., Uhas, K. A., Armstrong, L., Bosanko, K. A., Babovic-Vuksanovic, D., Baker, L., Basel, D. G., Bengala, M., Bennett, J. T., Chambers, C., Clarkson, L. K., Clementi, M., Cortés, F. M., Cunningham, M., D'Agostino, M. D., Delatycki, M. B., Digilio, M. C., Dosa, L., Esposito, S., Fox, S., Freckmann, M. L., Fauth, C., Giugliano, T., Giustini, S., Goetsch, A., Goldberg, Y., Greenwood, R. S., Griffis, C., Gripp, K. W., Gupta, P., Haan, E., Hachen, R. K., Haygarth, T. L., Hernández-Chico, C., Hodge, K., Hopkin, R. J., Hudgins, L., Janssens, S., Keller, K., Kelly-Mancuso, G., Kochhar, A., Korf, B. R., Lewis, A. M., Liebelt, J., Lichty, A., Listernick, R. H., Lyons, M. J., Maystadt, I., Martinez Ojeda, M., McDougall, C., McGregor, L. K., Melis, D., Mendelsohn, N., Nowaczyk, M. J. M., Ortenberg, J., Panzer, K., Pappas, J. G., Pierpont, M. E., Piluso, G., Pinna, V., Pivnick, E. K., Pond, D. A., Powell, C. M., Rogers, C., Ruhrman Shahar, N., Rutledge, S. L., Saletti, V., Sandaradura, S. A., Santoro, C., Schatz, U. A., Schreiber, A., Scott, D. A., Sellars, E. A., Sheffer, R., Siqveland, E., Slopis, J. M., Smith, R., Spalice, A., Stockton, D. W., Streff, H., Theos, A., Tomlinson, G. E., Tran, G., Trapane, P. L., Trevisson, E., Ullrich, N. J., Van den Ende, J., Schrier Vergano, S. A., Wallace, S. E., Wangler, M. F., Weaver, D. D., Yohay, K. H., Zackai, E., Zonana, J., Zurcher, V., Claes, K. B. M., Eoli, M., Martin, Y., Wimmer, K., De Luca, A., Legius, E., & Messiaen, L. M. (2020). Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat, 41(1), 299-315. https://doi.org/10.1002/humu.23929
    62. Lee, V., Ragge, N. K., & Collin, J. R. (2003). The surgical management of childhood orbito-temporal neurofibromatosis. Br J Plast Surg, 56(4), 380-387. https://doi.org/10.1016/s0007-1226(03)00172-3
    63. Legius, E., Messiaen, L., Wolkenstein, P., Pancza, P., Avery, R. A., Berman, Y., Blakeley, J., Babovic-Vuksanovic, D., Cunha, K. S., Ferner, R., Fisher, M. J., Friedman, J. M., Gutmann, D. H., Kehrer-Sawatzki, H., Korf, B. R., Mautner, V. F., Peltonen, S., Rauen, K. A., Riccardi, V., Schorry, E., Stemmer-Rachamimov, A., Stevenson, D. A., Tadini, G., Ullrich, N. J., Viskochil, D., Wimmer, K., Yohay, K., Huson, S. M., Evans, D. G., & Plotkin, S. R. (2021). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med, 23(8), 1506-1513. https://doi.org/10.1038/s41436-021-01170-5
    64. Lewis, R. A., & Riccardi, V. M. (1981). Von Recklinghausen neurofibromatosis. Incidence of iris hamartomata. Ophthalmology, 88(4), 348-354. https://doi.org/10.1016/s0161-6420(81)35034-9
    65. Listernick, R., Charrow, J., & Gutmann, D. H. (1999). Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet, 89(1), 38-44. https://doi.org/10.1002/(sici)1096-8628(19990326)89:1<38::aid-ajmg8>3.0.co;2-m
    66. Listernick, R., Ferner, R. E., Liu, G. T., & Gutmann, D. H. (2007). Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol, 61(3), 189-198. https://doi.org/10.1002/ana.21107
    67. Lovat, E., Siddique, M., Goh, V., Ferner, R. E., Cook, G. J. R., & Warbey, V. S. (2017). The effect of post-injection (18)F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. EJNMMI Res, 7(1), 35. https://doi.org/10.1186/s13550-017-0282-3
    68. Madden, J. R., Rush, S. Z., Stence, N., Foreman, N. K., & Liu, A. K. (2014). Radiation-induced gliomas in 2 pediatric patients with neurofibromatosis type 1: case study and summary of the literature. J Pediatr Hematol Oncol, 36(2), e105-108. https://doi.org/10.1097/mph.0000000000000006
    69. Madubata, C. C., Olsen, M. A., Stwalley, D. L., Gutmann, D. H., & Johnson, K. J. (2015). Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis. Genet Med, 17(1), 36-42. https://doi.org/10.1038/gim.2014.70
    70. Magro, G., Broggi, G., Angelico, G., Puzzo, L., Vecchio, G. M., Virzì, V., Salvatorelli, L., & Ruggieri, M. (2022). Practical Approach to Histological Diagnosis of Peripheral Nerve Sheath Tumors: An Update. Diagnostics (Basel), 12(6). https://doi.org/10.3390/diagnostics12061463
    71. Manolidis, S., Higuera, S., Boyd, V., & Hollier, L. H. (2006). Single-stage total and near-total resection of massive pediatric head and neck neurofibromas. J Craniofac Surg, 17(3), 506-510. https://doi.org/10.1097/00001665-200605000-00020
    72. Markham, A., & Keam, S. J. (2020). Selumetinib: First Approval. Drugs, 80(9), 931-937. https://doi.org/10.1007/s40265-020-01331-x
    73. Mautner, V. F., Hartmann, M., Kluwe, L., Friedrich, R. E., & Fünsterer, C. (2006). MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology, 48(3), 160-165. https://doi.org/10.1007/s00234-005-0033-4
    74. Mayerhofer, C., Niemeyer, C. M., & Flotho, C. (2021). Current Treatment of Juvenile Myelomonocytic Leukemia. J Clin Med, 10(14). https://doi.org/10.3390/jcm10143084
    75. Méni, C., Sbidian, E., Moreno, J. C., Lafaye, S., Buffard, V., Goldzal, S., Wolkenstein, P., & Valeyrie-Allanore, L. (2015). Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients. Dermatology, 230(3), 263-268. https://doi.org/10.1159/000368078
    76. Messiaen, L., Vogt, J., Bengesser, K., Fu, C., Mikhail, F., Serra, E., Garcia-Linares, C., Cooper, D. N., Lazaro, C., & Kehrer-Sawatzki, H. (2011). Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat, 32(2), 213-219. https://doi.org/10.1002/humu.21418
    77. Michimoto, K., Ashida, H., Higuchi, T., Kano, R., Hasumi, J., Suzuki, T., Ishida, K., Hirayama, H., & Ohta, A. (2021). Hemorrhagic Complication in Surgical Resection for Massive Plexiform Neurofibroma in Body Trunk: The Flow-Void Sign as a Predictor and Preoperative Embolization as Prevention. World J Surg, 45(12), 3603-3608. https://doi.org/10.1007/s00268-021-06299-7
    78. Miller, A. H., & Halloran, M. C. (2022). Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment. Dis Model Mech, 15(8). https://doi.org/10.1242/dmm.049422
    79. Miller, D. T., Freedenberg, D., Schorry, E., Ullrich, N. J., Viskochil, D., & Korf, B. R. (2019). Health Supervision for Children With Neurofibromatosis Type 1. Pediatrics, 143(5). https://doi.org/10.1542/peds.2019-0660
    80. Miyakoshi, N., Hongo, M., Kasukawa, Y., Misawa, A., & Shimada, Y. (2010). Bilateral and symmetric C1-C2 dumbbell ganglioneuromas associated with neurofibromatosis type 1 causing severe spinal cord compression. Spine J, 10(4), e11-15. https://doi.org/10.1016/j.spinee.2010.01.023
    81. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. (1988). Neurofibromatosis, 1(3), 172-178.
    82. National Multi-Center Treatment Collaboration Group For Neurofibromatosis, T., National Multi-Center Research Platform For, P., & Reconstructive, S. (2021). [Expert consensus on diagnosis and management of neurofibromatosis type 1 (2021 edition)]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 35(11), 1384-1395. https://doi.org/10.7507/1002-1892.202108065
    83. Ndiaye, L., Ndiaye, A., Foba, M. L., & Sankalé, A. A. (2020). [Management of cervico-cephalic plexiform neurofibromas: About 35 cases]. Ann Chir Plast Esthet, 65(4), 306-312. https://doi.org/10.1016/j.anplas.2020.03.002 (Prise en charge des neurofibromes plexiformes cervico-céphaliques : à propos de 35 cas.)
    84. Needle, M. N., Cnaan, A., Dattilo, J., Chatten, J., Phillips, P. C., Shochat, S., Sutton, L. N., Vaughan, S. N., Zackai, E. H., Zhao, H., & Molloy, P. T. (1997). Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994. J Pediatr, 131(5), 678-682. https://doi.org/10.1016/s0022-3476(97)70092-1
    85. Nelson, C. N., Dombi, E., Rosenblum, J. S., Miettinen, M. M., Lehky, T. J., Whitcomb, P. O., Hayes, C., Scott, G., Benzo, S., Widemann, B. C., & Chittiboina, P. (2019). Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg, 1-11. https://doi.org/10.3171/2019.7.Jns191353
    86. Nguyen, R., Dombi, E., Widemann, B. C., Solomon, J., Fuensterer, C., Kluwe, L., Friedman, J. M., & Mautner, V. F. (2012). Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis, 7, 75. https://doi.org/10.1186/1750-1172-7-75
    87. Nguyen, R., Ibrahim, C., Friedrich, R. E., Westphal, M., Schuhmann, M., & Mautner, V. F. (2013). Growth behavior of plexiform neurofibromas after surgery. Genet Med, 15(9), 691-697. https://doi.org/10.1038/gim.2013.30
    88. Nguyen, R., Kluwe, L., Fuensterer, C., Kentsch, M., Friedrich, R. E., & Mautner, V. F. (2011). Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr, 159(4), 652-655.e652. https://doi.org/10.1016/j.jpeds.2011.04.008
    89. Nicolin, G., Parkin, P., Mabbott, D., Hargrave, D., Bartels, U., Tabori, U., Rutka, J., Buncic, J. R., & Bouffet, E. (2009). Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer, 53(7), 1231-1237. https://doi.org/10.1002/pbc.22198
    90. Nix, J. S., Blakeley, J., & Rodriguez, F. J. (2020). An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol, 139(4), 625-641. https://doi.org/10.1007/s00401-019-02002-2
    91. Onesti, M. G., Carella, S., Spinelli, G., Martano, A., Giustini, S., & Scuderi, N. (2009). A study of 17 patients affected with plexiform neurofibromas in upper and lower extremities: comparison between different surgical techniques. Acta Chir Plast, 51(2), 35-40.
    92. Ortonne, N., Wolkenstein, P., Blakeley, J. O., Korf, B., Plotkin, S. R., Riccardi, V. M., Miller, D. C., Huson, S., Peltonen, J., Rosenberg, A., Carroll, S. L., Verma, S. K., Mautner, V., Upadhyaya, M., & Stemmer-Rachamimov, A. (2018). Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology, 91(2 Suppl 1), S5-s13. https://doi.org/10.1212/wnl.0000000000005792
    93. Patel, N. B., & Stacy, G. S. (2012). Musculoskeletal manifestations of neurofibromatosis type 1. AJR Am J Roentgenol, 199(1), W99-106. https://doi.org/10.2214/ajr.11.7811
    94. Pecoraro, A., Arehart, E., Gallentine, W., Radtke, R., Smith, E., Pizoli, C., Kansagra, S., Abdelnour, E., McLendon, R., & Mikati, M. A. (2017). Epilepsy in neurofibromatosis type 1. Epilepsy Behav, 73, 137-141. https://doi.org/10.1016/j.yebeh.2017.05.011
    95. Pinna, V., Daniele, P., Calcagni, G., Mariniello, L., Criscione, R., Giardina, C., Lepri, F. R., Hozhabri, H., Alberico, A., Cavone, S., Morella, A. T., Mandile, R., Annunziata, F., Di Giosaffatte, N., D'Asdia, M. C., Versacci, P., Capolino, R., Strisciuglio, P., Giustini, S., Melis, D., Digilio, M. C., Tartaglia, M., Marino, B., & De Luca, A. (2019). Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease. Genes (Basel), 10(9). https://doi.org/10.3390/genes10090675
    96. Pobric, G., Taylor, J. R., Ramalingam, H. M., Pye, E., Robinson, L., Vassallo, G., Jung, J., Bhandary, M., Szumanska-Ryt, K., Theodosiou, L., Evans, D. G., Eelloo, J., Burkitt-Wright, E., Hulleman, J., Green, J., & Garg, S. (2022). Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1. J Autism Dev Disord, 52(4), 1478-1494. https://doi.org/10.1007/s10803-021-05043-3
    97. Poyrazoğlu, H. G., Baş, V. N., Arslan, A., Bastug, F., Canpolat, M., Per, H., Gümüs, H., & Kumandas, S. (2017). Bone mineral density and bone metabolic markers' status in children with neurofibromatosis type 1. J Pediatr Endocrinol Metab, 30(2), 175-180. https://doi.org/10.1515/jpem-2016-0092
    98. Prada, C. E., Rangwala, F. A., Martin, L. J., Lovell, A. M., Saal, H. M., Schorry, E. K., & Hopkin, R. J. (2012). Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr, 160(3), 461-467. https://doi.org/10.1016/j.jpeds.2011.08.051
    99. Quaranta, L., Semeraro, F., Turano, R., & Gandolfo, E. (2004). Gonioscopic findings in patients with type 1 neurofibromatosis (Von Recklinghausen disease). J Glaucoma, 13(2), 90-95. https://doi.org/10.1097/00061198-200404000-00002
    100. Ragge, N. K., Falk, R. E., Cohen, W. E., & Murphree, A. L. (1993). Images of Lisch nodules across the spectrum. Eye (Lond), 7 ( Pt 1), 95-101. https://doi.org/10.1038/eye.1993.20
    101. Rana, M., Essig, H., Eckardt, A. M., Tavassol, F., Ruecker, M., Schramm, A., & Gellrich, N. C. (2012). Advances and innovations in computer-assisted head and neck oncologic surgery. J Craniofac Surg, 23(1), 272-278. https://doi.org/10.1097/SCS.0b013e318241bac7
    102. Ransom, E. R., Yoon, C., & Manolidis, S. (2006). Single stage near total resection of massive pediatric head and neck plexiform neurofibromas. Int J Pediatr Otorhinolaryngol, 70(6), 1055-1061. https://doi.org/10.1016/j.ijporl.2005.10.025
    103. Riccardi, V. M. (1993). Neurofibromatosis: Phenotype, Natural History and Pathogenesis. Plastic and Reconstructive Surgery, 91(3), 561. https://journals.lww.com/plasreconsurg/fulltext/1993/03000/neurofibromatosis__phenotype,_natural_history_and.29.aspx
    104. Roberts, A. E., Allanson, J. E., Tartaglia, M., & Gelb, B. D. (2013). Noonan syndrome. Lancet, 381(9863), 333-342. https://doi.org/10.1016/s0140-6736(12)61023-x
    105. Rodriguez, F. J., Folpe, A. L., Giannini, C., & Perry, A. (2012). Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol, 123(3), 295-319. https://doi.org/10.1007/s00401-012-0954-z
    106. Roy, A., Roulin, J. L., Gras-Le Guen, C., Corbat, M. L., & Barbarot, S. (2021). Executive functions and quality of life in children with neurofibromatosis type 1. Orphanet J Rare Dis, 16(1), 420. https://doi.org/10.1186/s13023-021-02051-5
    107. Sani, I., & Albanese, A. (2017). Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma . Horm Res Paediatr, 87(3), 179-188. https://doi.org/10.1159/000458525
    108. Schaefer, I. M., & Fletcher, C. D. (2015). Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: clinicopathologic characterization in a series of 9 cases. Am J Surg Pathol, 39(9), 1234-1241. https://doi.org/10.1097/pas.0000000000000447
    109. Sippel, K. C. (2001). Ocular findings in neurofibromatosis type 1. Int Ophthalmol Clin, 41(1), 25-40. https://doi.org/10.1097/00004397-200101000-00005
    110. Sorrentino, U., Bellonzi, S., Mozzato, C., Brasson, V., Toldo, I., Parrozzani, R., Clementi, M., Cassina, M., & Trevisson, E. (2021). Epilepsy in NF1: Epidemiologic, Genetic, and Clinical Features. A Monocentric Retrospective Study in a Cohort of 784 Patients. Cancers (Basel), 13(24). https://doi.org/10.3390/cancers13246336
    111. Stewart, D. R., Korf, B. R., Nathanson, K. L., Stevenson, D. A., & Yohay, K. (2018). Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 20(7), 671-682. https://doi.org/10.1038/gim.2018.28
    112. Suarez-Kelly, L. P., Yu, L., Kline, D., Schneider, E. B., Agnese, D. M., & Carson, W. E. (2019). Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hered Cancer Clin Pract, 17, 12. https://doi.org/10.1186/s13053-019-0110-z
    113. Taylor, L. A., & Lewis, V. L., Jr. (2019). Neurofibromatosis Type 1: Review of Cutaneous and Subcutaneous Tumor Treatment on Quality of Life. Plast Reconstr Surg Glob Open, 7(1), e1982. https://doi.org/10.1097/gox.0000000000001982
    114. Thomas, P. K., King, R. H., Chiang, T. R., Scaravilli, F., Sharma, A. K., & Downie, A. W. (1990). Neurofibromatous neuropathy. Muscle Nerve, 13(2), 93-101. https://doi.org/10.1002/mus.880130202
    115. Tornese, G., Faleschini, E., Matarazzo, L., Bibalo, C., Zanazzo, G. A., Rabusin, M., Tonini, G., Zennaro, F., & Ventura, A. (2015). Relapse and metastasis of atypical teratoid/rhabdoid tumor in a boy with neurofibromatosis type 1 treated with recombinant human growth hormone. Neuropediatrics, 46(2), 126-129. https://doi.org/10.1055/s-0034-1393706
    116. Toro, G., Santoro, C., Ambrosio, D., Landi, G., Scilipoti, M., Moretti, A., Paoletta, M., Liguori, S., Schiavone Panni, A., Picariello, S., & Iolascon, G. (2021). Natural History of Scoliosis in Children with NF1: An Observation Study. Healthcare (Basel), 9(7). https://doi.org/10.3390/healthcare9070881
    117. Torres Nupan, M. M., Velez Van Meerbeke, A., López Cabra, C. A., & Herrera Gomez, P. M. (2017). Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr, 5, 227. https://doi.org/10.3389/fped.2017.00227
    118. Vassilopoulou-Sellin, R., Klein, M. J., & Slopis, J. K. (2000). Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr Neurol, 22(5), 355-358. https://doi.org/10.1016/s0887-8994(00)00123-5
    119. Vetrano, I. G., Saletti, V., & Nazzi, V. (2019). Fluorescein-guided resection of plexiform neurofibromas: how I do it. Acta Neurochir (Wien), 161(10), 2141-2145. https://doi.org/10.1007/s00701-019-04038-5
    120. Viola, F., Villani, E., Natacci, F., Selicorni, A., Melloni, G., Vezzola, D., Barteselli, G., Mapelli, C., Pirondini, C., & Ratiglia, R. (2012). Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology, 119(2), 369-375. https://doi.org/10.1016/j.ophtha.2011.07.046
    121. Vitale, M. G., Guha, A., & Skaggs, D. L. (2002). Orthopaedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res(401), 107-118. https://doi.org/10.1097/00003086-200208000-00013
    122. von Mehren, M., Kane, J. M., Agulnik, M., Bui, M. M., Carr-Ascher, J., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., Gonzalez, R. J., Holder, A., Homsi, J., Keedy, V., Kelly, C. M., Kim, E., Liebner, D., McCarter, M., McGarry, S. V., Mesko, N. W., Meyer, C., Pappo, A. S., Parkes, A. M., Petersen, I. A., Pollack, S. M., Poppe, M., Riedel, R. F., Schuetze, S., Shabason, J., Sicklick, J. K., Spraker, M. B., Zimel, M., Hang, L. E., Sundar, H., & Bergman, M. A. (2022). Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(7), 815-833. https://doi.org/10.6004/jnccn.2022.0035
    123. Vurallı, D., Gönç, N., Vidaud, D., Özön, A., Alikaşifoğlu, A., & Kandemir, N. (2016). Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome. J Clin Res Pediatr Endocrinol, 8(1), 96-100. https://doi.org/10.4274/jcrpe.2070
    124. Wang, R., & Lin, Z. (2021). A child with multiple hypopigmented lesions. Bmj, 372, m4844. https://doi.org/10.1136/bmj.m4844
    125. Warbey, V. S., Ferner, R. E., Dunn, J. T., Calonje, E., & O'Doherty, M. J. (2009). [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging, 36(5), 751-757. https://doi.org/10.1007/s00259-008-1038-0
    126. Weleber, R. G., & Zonana, J. (1983). Iris hamartomas (Lisch nodules) in a case of segmental neurofibromatosis. Am J Ophthalmol, 96(6), 740-743. https://doi.org/10.1016/s0002-9394(14)71917-8
    127. Well, L., Döbel, K., Kluwe, L., Bannas, P., Farschtschi, S., Adam, G., Mautner, V. F., & Salamon, J. (2021). Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth. PLoS Genet, 17(5), e1009517. https://doi.org/10.1371/journal.pgen.1009517
    128. Wise, J. B., Cryer, J. E., Belasco, J. B., Jacobs, I., & Elden, L. (2005). Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1. Arch Otolaryngol Head Neck Surg, 131(8), 712-718. https://doi.org/10.1001/archotol.131.8.712
    129. Wise, J. B., Patel, S. G., & Shah, J. P. (2002). Management issues in massive pediatric facial plexiform neurofibroma with neurofibromatosis type 1. Head Neck, 24(2), 207-211. https://doi.org/10.1002/hed.10001
    130. Yagi, T., Ohata, K., Haque, M., & Hakuba, A. (1997). Intramedullary spinal cord tumour associated with neurofibromatosis type 1. Acta Neurochir (Wien), 139(11), 1055-1060. https://doi.org/10.1007/bf01411560
    131. Yao, R., Wang, L., Yu, Y., Wang, J., & Shen, Y. (2016). Diagnostic value of multiple café-au-lait macules for neurofibromatosis 1 in Chinese children. J Dermatol, 43(5), 537-542. https://doi.org/10.1111/1346-8138.13169
    132. Zessis, N. R., Gao, F., Vadlamudi, G., Gutmann, D. H., & Hollander, A. S. (2018). Height Growth Impairment in Children With Neurofibromatosis Type 1 Is Characterized by Decreased Pubertal Growth Velocity in Both Sexes. J Child Neurol, 33(12), 762-766. https://doi.org/10.1177/0883073818786807
    133. Zhao, S., Zhang, Y., Chen, W., Li, W., Wang, S., Wang, L., Zhao, Y., Lin, M., Ye, Y., Lin, J., Zheng, Y., Liu, J., Zhao, H., Yan, Z., Yang, Y., Huang, Y., Lin, G., Chen, Z., Zhang, Z., Liu, S., Jin, L., Wang, Z., Chen, J., Niu, Y., Li, X., Wu, Y., Wang, Y., Du, R., Gao, N., Zhao, H., Yang, Y., Liu, Y., Tian, Y., Li, W., Zhao, Y., Liu, J., Yu, B., Zhang, N., Yu, K., Yang, X., Li, S., Xu, Y., Hu, J., Liu, Z., Shen, J., Zhang, S., Su, J., Khanshour, A. M., Kidane, Y. H., Ramo, B., Rios, J. J., Liu, P., Sutton, V. R., Posey, J. E., Wu, Z., Qiu, G., Wise, C. A., Zhang, F., Lupski, J. R., Zhang, J., & Wu, N. (2021). Diagnostic yield and clinical impact of exome sequencing in early-onset scoliosis (EOS). J Med Genet, 58(1), 41-47. https://doi.org/10.1136/jmedgenet-2019-106823
    134. Goldblum, J. R., Folpe, A. L., Weiss, S. W. Enzinger & Weiss′s soft tissue tumors, Sixth
    135. edition. Elsevier: Philadelphia, PA, 2014: 855⁃879.
    136. Tadini, G., Legius, E., Brems, H. Multidisciplinary approach to neurofibromatosis type 1.
    137. Switzerland, Springer, 2020: 45⁃69.
    138. Beiyao ZHU, Chengjiang Wei, et,al. Treatment and progress of cutaneous neurofibroma
    139. Chinese Journal of Reparative and Reconstructive Surgery,2022,36 (9): 1064⁃1071. Chinese. Doi:10.7507/1002-1892.202205072
    140. Chinese society of clinical oncology. CSCO guideline for soft tissue sarcoma. Peple’s
    141. medical publishing house Co., LTD,2022.
    142. Y Cui, Y Li, Z J Hou, et al. Clinical features and surgical management of orbitotemporal
    143. neurofibromatosis. Zhonghua Yan Ke Za Zhi 2019, 55 (11): 828⁃833. Chinese Doi: 10.3760/cma.j.issn.0412-4081.2019.11.008
    144. Xiaodan Long, Jing Xiong, et al. A case of growth hormone deficiency combined with
    145. neurofibromatosis type 1 and its gene analysis. J Cent South Univ(Med Sci), 2018, 43 (7): 811⁃815. Chinese Doi: 10.11817/j.issn.1672-7347.2018.07.018
    146. Mei Zhang, Yanying Li, et al. Diagnostic features and literature review of short stature with
    147. neurofibromatosis type 1. Chinese Journal of Diagnostics, 2014, 2 (2): 114⁃115. Chinese Doi: 10.3877/cma.j.issn.2095-655X.2014.02.010

    How to Cite

    “Guidelines for the Multidisciplinary Diagnosis and Treatment of Neurofibromatosis Type 1 (2023 Version) Multidisciplinary Diagnosis and Treatment Collaboration Group for Neurofibromatosis Type 1 of China Alliance for Rare Diseases”. Human Brain, vol. 3, no. 3, Nov. 2024, https://doi.org/10.37819/hb.3.2025.
    ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
    Download Citation
    Endnote/Zotero/Mendeley (RIS) BibTeX

    How to Cite

    “Guidelines for the Multidisciplinary Diagnosis and Treatment of Neurofibromatosis Type 1 (2023 Version) Multidisciplinary Diagnosis and Treatment Collaboration Group for Neurofibromatosis Type 1 of China Alliance for Rare Diseases”. Human Brain, vol. 3, no. 3, Nov. 2024, https://doi.org/10.37819/hb.3.2025.

    HTML
    3

    Total

    Share

    Search Panel

    Yicheng Zhu
    Google Scholar
    Pubmed
    JDMFS Journal

    Downloads

    Article Details

    Most Read This Month

    License

    Copyright (c) 2024 Yicheng Zhu

    Creative Commons License

    This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

    Copyright © 2023 EurAsia Academic Publishing Group. All rights reserved